WA-T-MOBILE
20.9.2022 02:25:37 CEST | Business Wire | Press release
Today, T-Mobile (NASDAQ: TMUS) announced that ICE Cobotics, a global leader in cleaning technologies and equipment, has chosen T IoT as its exclusive IoT connectivity solution worldwide to help their customers more easily manage fleets of floor cleaning robots.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220919005555/en/
Floor cleaning and technology company picks T IoT to power i-SYNERGY fleet management software and strengthen its global subscription service (Photo: Business Wire)
As part of the long-term agreement, T IoT — a comprehensive solution for global IoT connectivity, platform management and support — will deliver cellular connectivity to more than 7,500 new and existing ICE Cobotics intelligent and autonomous cleaning units across the world. This includes their newest product, Cobi 18, a compact autonomous floor scrubber which is designed to clean 5,000 to 7,000 square feet per hour, starting at less than $20 a day.
ICE Cobotics chose T IoT to simplify the delivery and execution of IoT solutions on a global scale, which bolsters their mission to streamline processes for its customers. Less than a year ago, the company launched an industry first: an all-inclusive subscription service for floor cleaning machines, parts and maintenance, and performance and monitoring software. The service provides customers with a more reliable, affordable, and cost predictive solution, allowing them to use their capital to expand their business versus having it tied up in equipment ownership.
T IoT supports ICE Cobotics’ subscription model by delivering cleaning performance data and insights to customers in the retail, grocery, convenience, healthcare, higher education, and hospitality industries. Imagine a major retail corporation that has hundreds of robots in service. The cellular connectivity allows a customer’s maintenance and facilities team to view their Clean Score — goal-based cleaning performance data generated by ICE Cobotics’ i-SYNERGY fleet management software. This takes the guess work out of tracking cleaning efficacy, developing efficiencies, and confirming each location is clean. Previously, they would have had to visit each store to inspect if cleaning happened, which takes time and money.
Additionally, T IoT reinforces ICE Cobotics’ commitment to eliminate downtime by delivering over the air software and firmware updates to its customers, as well as mechanical telemetry data, from sensors and cameras in each machine, back to the company. This gives them the ability to monitor and analyze critical information like hours of use, routes, temperature, and battery life — so they can determine if certain components of a machine are operating within tolerance, if service is required and if a part is near its end of life — to prevent problems before they happen.
“T IoT is critical to the success of our cleaning machines and our all-inclusive subscription service,” said Mike DeBoer, President, ICE Cobotics U.S. “The data we receive from our autonomous scrubbers allows us to deliver cleaning performance insights and an enhanced clean to our customers at an affordable price.”
“This is what T IoT was designed for — helping enterprises solve global IoT challenges and deliver innovative solutions that make their customers want more,” said Callie Field, President, T-Mobile Business Group. “Like ICE Cobotics, T-Mobile and Deutsche Telekom share a passion for the pursuit of simple and we salute their ongoing mission to make things easier for their customers.”
To learn more about ICE Cobotics, visit www.us.icecobotics.com.
For more information about T IoT, visit www.t-mobile.com/business/solutions/iot/t-iot-global.
Follow T-Mobile’s Official Twitter Newsroom @TMobileNews to stay up to date with the latest company news.
About T-Mobile
T-Mobile US, Inc. (NASDAQ: TMUS) is America’s supercharged Un-carrier, delivering an advanced 4G LTE and transformative nationwide 5G network that will offer reliable connectivity for all. T-Mobile’s customers benefit from its unmatched combination of value and quality, unwavering obsession with offering them the best possible service experience and undisputable drive for disruption that creates competition and innovation in wireless and beyond. Based in Bellevue, Wash., T-Mobile provides services through its subsidiaries and operates its flagship brands, T-Mobile and Metro by T-Mobile. For more information please visit: https://www.t-mobile.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220919005555/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
NTT DOCOMO BUSINESS and Chile’s State-owned Copper Company CODELCO Launch a Study and Proof of Concept Aimed at Improving the Efficiency of Remote Copper Mine Operations Using IOWN® APN6.8.2026 06:30:00 CEST | Press release
NTT DOCOMO BUSINESS, Inc. (formerly NTT Communications Corporation) has launched a study and proof of concept jointly with Corporación Nacional del Cobre de Chile (CODELCO) to progress remote operations at CODELCO’s copper mines using an IOWN® All-Photonics Network (APN).1 This initiative is part of a research project commissioned by Japan’s Ministry of Internal Affairs and Communications.2 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260806845222/en/ Conceptual Diagram of the Demonstration To address operational challenges faced by CODELCO’s copper mines, the initiative will connect a copper mine and a remote operations center—approximately 1,500 km apart—via an IOWN APN. It will assess the feasibility of remotely operating heavy machinery using high-capacity, low-latency communication links, enhancing monitoring operations through high-definition video, and implementing a remote operations model. 1. Background Chile is o
FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release
Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into
U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release
Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR
Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted
Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release
Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom